Clinical comparison · GLP-1 / weight loss
Tirzepatide vs Retatrutide
Tirzepatide is the current best-in-class dual agonist. Retatrutide is the triple agonist behind it in the pipeline with larger phase-2 weight-loss numbers.
Attribute
Tirzepatide
Retatrutide
Mechanism
Dual GIP/GLP-1 receptor agonist. Additive satiety, insulin secretion, and glucagon suppression.
Triple agonist of GLP-1, GIP, and glucagon receptors. Adds glucagon-driven energy expenditure to GLP-1/GIP satiety and insulinotropic effects.
Standard dosing
2.5 mg weekly, titrated q4 weeks up to 15 mg maintenance.
2 mg weekly, titrated q4 weeks toward 8–12 mg maintenance in trials.
Indications
- Medical weight loss
- Type 2 diabetes (branded)
- Metabolic syndrome
- Medical weight loss (investigational)
- Metabolic syndrome
- Severe obesity
Strengths
- Superior weight-loss outcomes vs semaglutide in trials
- Broader dose range for tolerance-matching
- Largest weight-loss magnitude in phase-2 trials
- Adds glucagon axis for energy expenditure
Cautions
- More expensive
- Same MTC / pancreatitis contraindications
- Gallbladder monitoring
- Investigational, not FDA-approved
- Not broadly compounded
- Same MTC/pancreatitis cautions as GLP-1s
Choose Tirzepatide when
Patient needs an available, compoundable agent with strong outcomes today.
Wholesale Tirzepatide →Choose Retatrutide when
Practice is tracking pipeline agents or offering an investigational-adjacent program under proper protocol.
Wholesale Retatrutide →FAQs
- Is retatrutide available for compounding?
- Not broadly. Availability is limited and clinics should verify sourcing and 503A eligibility before offering it.
- Does the glucagon axis cause hyperglycemia?
- Net effect in trials is weight loss with improved glycemic control; the GLP-1 and GIP components dominate glucose handling.